(Q33703096)

English

Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board (English)

1 reference

Europe PubMed Central

28 July 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

peripheral neuropathy

1 reference

based on heuristic

inferred from title

author name string

Joseph D Tariman

1

1 reference

Europe PubMed Central

28 July 2017

Ginger Love

2

1 reference

Europe PubMed Central

28 July 2017

Emily McCullagh

3

1 reference

Europe PubMed Central

28 July 2017

Stacey Sandifer

4

1 reference

Europe PubMed Central

28 July 2017

IMF Nurse Leadership Board

5

1 reference

Europe PubMed Central

28 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 June 2008

1 reference

Europe PubMed Central

28 July 2017

Clinical Journal of Oncology Nursing

1 reference

Europe PubMed Central

28 July 2017

12

1 reference

Europe PubMed Central

28 July 2017

29-36

1 reference

Europe PubMed Central

28 July 2017

3 Suppl

1 reference

Europe PubMed Central

28 July 2017

Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

The emerging role of novel therapies for the treatment of relapsed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Advances in oral therapy in the treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Neurological aspects of multiple myeloma and related disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Updating your peripheral neuropathy "know-how".

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Thalidomide: current therapeutic uses and management of its toxicities.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Understanding peripheral neuropathy in patients with cancer: background and patient assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Thalidomide in cancer: potential uses and limitations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

14 July 2018

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

30 October 2018

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

30 October 2018

Bradycardia during therapy for multiple myeloma with thalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

30 October 2018

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4042669

30 October 2018

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Total neuropathy score: validation and reliability study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuropathies associated with paraproteinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy-induced peripheral neuropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

1 reference

https://pubmed.ncbi.nlm.nih.gov/18490255

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1188/08.CJON.S1.29-35

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33703096&oldid=1634384959"